PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $5,407 | +1169.2% | 195,756 | +957.3% | 0.04% | +720.0% |
Q1 2023 | $426 | -31.6% | 18,515 | -67.6% | 0.01% | -37.5% |
Q4 2022 | $623 | -99.9% | 57,121 | -43.0% | 0.01% | -20.0% |
Q3 2022 | $845,000 | -30.2% | 100,200 | -34.5% | 0.01% | -23.1% |
Q2 2022 | $1,210,000 | +55.1% | 153,033 | +364.3% | 0.01% | +116.7% |
Q1 2022 | $780,000 | -40.8% | 32,959 | -14.5% | 0.01% | -14.3% |
Q4 2021 | $1,318,000 | +284.3% | 38,550 | +99.1% | 0.01% | +250.0% |
Q3 2021 | $343,000 | +172.2% | 19,366 | +589.2% | 0.00% | +100.0% |
Q2 2021 | $126,000 | -44.2% | 2,810 | -67.8% | 0.00% | 0.0% |
Q1 2021 | $226,000 | +113.2% | 8,725 | +61.0% | 0.00% | 0.0% |
Q3 2020 | $106,000 | -51.2% | 5,420 | -55.8% | 0.00% | -50.0% |
Q2 2020 | $217,000 | – | 12,264 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |